Tirzepatide is a dual GIP and GLP-1 receptor agonist, mimicking the effects of endogenous GIP while inducing cAMP synthesis at the GLP-1 receptor. This unique mechanism induces a synergistic effect with enhanced insulin response and glucagonostatic activity, versus GIP or GLP-1 therapy alone. Following extensive clinical testing, including against comparable treatments, tirzepatide was approved in May 2022 by the United State Food and Drug Administration (USFDA) as a type 2 diabetes (T2D) treatment. It became the first dual GLP-1 and GIP receptor agonist indicated for T2D

Benefits of Tirzepatide may include: Weight loss, diabetes, In a 26-week study on T2D patients, once-weekly tirzepatide injections improved lipoprotein biomarkers associated with insulin resistance and cardiovascular risk, while reducing triglycerides, suggesting a net lowering of the patients’ risk of heart disease